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In patients with left ventricular (LV) dysfunction in the
setting of an acute myocardial infarction (MI), current
guidelines recommend implantable cardioverter-deﬁbrillator
(ICD) implantation only after waiting at least 40 days or
3 months, depending on whether the patient was revascu-
larized or not (1). This is despite evidence that the early
post-MI patient is potentially at signiﬁcant risk of sudden
cardiac death (SCD) and that long-term, ICDs are effective
in preventing SCD. These recommendations stem directly
from the results of 2 randomized clinical studies: The
DINAMIT (Deﬁbrillator in Acute Myocardial Infarction
Trial) (2) and IRIS (Immediate Risk-Stratiﬁcation
Improves Survival) (3) studies were both clinical trials that
randomized patients early after acute MI to receive optimal
medical therapy with or without an ICD. Both showed no
mortality beneﬁt in patients receiving an ICD versus those
who did not. Hence, the current state of affairs leaves
a signiﬁcant population of patients immediately after MI
who may be at risk of arrhythmia-mediated SCD in a “gap
of vulnerability.”See page 2000The reasons for the lack of beneﬁt of early ICD im-
plantation after MI are unclear. Although both DINAMIT
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had an increased risk of nonarrhythmic death that essentially
offset the beneﬁt of the ICD. Those higher-risk patients
tended toward elevated baseline heart rate, suggesting
increased sympathetic tone and poorer clinical status. Some
portion of the post-MI population will eventually recover
LV function, rendering them at lower risk of SCD. More-
over, causes of sudden death in this patient population may
also be nonarrhythmic, including reinfarction and LV wall
rupture (4).
The wearable cardioverter-deﬁbrillator (WCD) was
approved by the U.S. Food and Drug Administration in
2002, with indications for use in patients who are at risk of
SCD but are unable or unwilling to receive an ICD (5).
According to guidelines from the American College of
Cardiology/American Heart Association/European Society
of Cardiology and others, candidates for a WCD include
patients who are at high risk after recent MI or cardiac
intervention, who have had an ICD removed due to infec-
tion, and who are awaiting reimplantation, or who are
awaiting cardiac transplantation (1); however, there are no
randomized trials evaluating the efﬁcacy of WCD in these
settings.
To date, there have only been a handful of studies evalu-
ating the efﬁcacy of the WCD, with particularly few focused
on early post-MI patient populations. The WEARIT/
BIROAD (6) trial, initially two separate clinical studies that
the U.S. Food and Drug Administration requested be
combined into a single study, evaluated 289 patients with
indications for a WCD in a nonrandomized fashion. Six of 8
appropriate therapies were successful, with failures attributed
to incorrect device placement (6). Chung et al. (7) reported
the outcomes among patients (n¼ 3,569) tracked in a registry
sponsored by the manufacturer of the WCD (LifeVest, Zoll,
Pittsburgh, Pennsylvania), of which 21.4% had depressed LV
function and recent MI or coronary artery bypass graft
(CABG) surgery. Among this subset of 584 patients, 12
(2.1%) received appropriate WCD therapies for ventricular
arrhythmia (VA). Zishiri et al. (8) compared patients after
percutaneous coronary intervention or CABG with left
ventricular ejection fraction (EF) 35% with or without
WCD therapy; the treated cohort was derived again from the
manufacturer’s database and compared with a single-center
post–percutaneous coronary intervention or post-CABG
population. Mortality was signiﬁcantly lower in the WCD
versus the non-WCD group (3% vs. 7%), and the rate of
appropriate WCD therapy was 1.3%.
In this issue of the Journal, Epstein et al. (9) attempt to
address the speciﬁc question of whether the WCD can impart
protection against SCD in the patient group with depressed
LV function immediately after acute MI, prior to ICD eligi-
bility, using the aforementioned manufacturer’s database. The
investigators culled patients prescribed aWCDwith acute MI
and EF 35%; 8,543 patients fell within this gap population.
Among these, 133 patients (1.6%) received appropriate
shocks, of whom 91% survived the treated event; WCD
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2009successfully converted 209 of 252 VA events (81.6%). Overall
survival in this group was 73% after 3 months, compared with
96% in patients who were not treated. The investigators point
out that, given the caveat of slightly different populations in
each study, the overall mortality rate of 4% in their WCD
cohort is higher than that observed in DINAMIT (1.8%) and
IRIS (2.9%). This may very well be due to the selection bias
inherent in the manufacturer’s database, or perhaps the likely
tighter control of medical therapy inherent in randomized
trials such as DINAMIT or IRIS. The investigators also point
out the similarity in rates of treated VA in their cohort
compared with the rate of sudden death in the VALIANT
(Valsartan in Acute Myocardial Infarction Trial) (1.4% at 30
days and 2.5% between 1 and 6 months), with the caveat that
accurately attributing the deaths in VALIANT to ventricular
arrhythmias was not possible. In fact, autopsy ﬁndings suggest
that about one-half of the deaths in VALIANT may be
nonarrhythmic (4).
Given the limitations inherent in using a manufacturer’s
database and in comparing the results of clinical studies with
divergent patient populations, methodologies, and goals, it
seems we can still draw some conclusions from this current
study. First, there is a small but deﬁnite subpopulation of
post-MI patients who are at risk of SCD during the
mandated waiting period for ICD implantation. Patients
who received appropriate WCD therapy appear to have
increased mortality. Whether this is due to the negative
impact of VA on clinical status, or that VA is a marker for
poor clinical outcomes, or that the shocks themselves
contribute to clinical destabilization is unclear. It is also not
clear whether those who received inappropriate WCD
therapies also had poorer outcomes. That being said, this
population appears effectively treated by the WCD for VA.
There are potential additional beneﬁts of the WCD that
are more difﬁcult to assess. As the WCD is essentially an
event recorder, patients with WCD are likely more closely
monitored. Compliance with WCD is high (7), and it is
possible the constant, conspicuous reminder of one’s
vulnerability to SCD may increase patient compliance to the
medical regimen. Currently, the primary alternative nonin-
vasive intervention is the automated external deﬁbrillator.
Comparative efﬁcacy between the automated external deﬁ-
brillator and WCD has never been evaluated, but it stands to
reason that the more complete monitoring with the WCD
makes arrhythmia detection more likely. Finally, the sartorial
considerations of the WCD patient are unclear.
A major limitation to this study is the selection bias
inherent in the database used. Patients deemed at particu-
larly high risk are more likely targeted for WCD therapy, as
the high mortality rate of patients in the database attests. To
point, a randomized clinical trial (Vest Prevention of Early
Sudden Death Trial and VEST Registry) is currently
enrolling patients and will hopefully address this concern.
Another important limitation of this study is the lack of
data about potential arrhythmia underdetection with theWCD. However, given the low mortality rate in nontreated
patients, it is likely that few lethal arrhythmias were
underdetected.
So in the end, this study still does not quite answer the
elusive question of how to best risk-stratify post-MI low-EF
patients in the early days after infarction. Some portion will
go on to recover LV function, whereas others will fail to do
so and will eventually meet criteria for ICD therapy. A
fraction of patients will suffer SCD during this waiting
period. Does the relatively low incidence of risk within this
period warrant prescribing a WCD for every patient with
low EF after MI? Should the WCD be prescribed for a ﬁxed
duration? If not, what are the criteria for determining when
it is safe to stop wearing the WCD? Despite these unan-
swered questions, this study provides a bit more enlighten-
ment on this challenging subject.
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